Gelomulide N is primarily investigated for its potential antitumor and anticancer properties. It functions as a microtubule-destabilizing agent, interfering with cell division by inhibiting the polymerization of tubulin, which is essential for mitotic spindle formation. This mechanism leads to cell cycle arrest and induces apoptosis in rapidly dividing cancer cells. Due to this activity, Gelomulide N has drawn interest as a lead compound in the development of novel chemotherapeutic agents, particularly for solid tumors and multidrug-resistant cancers. Its structural complexity also makes it a target for synthetic studies aimed at producing analogs with improved efficacy and reduced toxicity. Research remains largely in the preclinical stage, focusing on structure-activity relationships and delivery methods to enhance bioavailability.